CHUNGBUK NATIONAL UNIVERSITY HOSPITAL
- Country
- 🇰🇷South Korea
- Ownership
- -
- Established
- 1988-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.cbnuh.or.kr/
Clinical Trials
25
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Comparing Active Cycle of Breathing Techniques (ACBT) and Aerobika in Treating Bronchiectasis in Korea
- Conditions
- BronchiectasisBronchiectasis With Acute Exacerbation
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07037303
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Efficacy and Safety of Remimazolam Compared With Midazolam During Bronchoscopy:Randomised Controlled Trial
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05994547
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: INS
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05103306
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes MellitusGlucose, High Blood
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04893148
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheonju, Chungcheongbuk-do, Korea, Republic of
Tepotinib in Solid Tumors Harboring MET Alterations
- Conditions
- Solid TumorMET Exon 14 Skipping MutationMET Amplification
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04647838
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Chonnam, Korea, Republic of
🇰🇷Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷Dankook University Hospital, Cheonan, Korea, Republic of
- Prev
- 1
- 2
- Next
News
Korean Hospitals Secure Approval for SK Biopharmaceuticals' Cenobamate for Epilepsy Treatment
Two major Korean university hospitals have received therapeutic use approval for cenobamate in epilepsy treatment, marking the first medical team applications for this indication since SK Biopharmaceuticals' 2022 approval.